Last reviewed · How we verify

Benzalkonium chloride (BAK) — Competitive Intelligence Brief

Benzalkonium chloride (BAK) (Benzalkonium chloride (BAK)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Quaternary ammonium compound / Antimicrobial preservative. Area: Ophthalmology / Dermatology / Antimicrobial.

marketed Quaternary ammonium compound / Antimicrobial preservative Ophthalmology / Dermatology / Antimicrobial Small molecule Live · refreshed every 30 min

Target snapshot

Benzalkonium chloride (BAK) (Benzalkonium chloride (BAK)) — Gangnam Severance Hospital. Benzalkonium chloride is a quaternary ammonium compound that disrupts bacterial and fungal cell membranes, exerting antimicrobial and preservative effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Benzalkonium chloride (BAK) TARGET Benzalkonium chloride (BAK) Gangnam Severance Hospital marketed Quaternary ammonium compound / Antimicrobial preservative

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Quaternary ammonium compound / Antimicrobial preservative class)

  1. Gangnam Severance Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Benzalkonium chloride (BAK) — Competitive Intelligence Brief. https://druglandscape.com/ci/benzalkonium-chloride-bak. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: